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Abstract The role of members of the mitogen-activated protein
kinase (MAPK) family on tumor necrosis factor K (TNF-K)-
mediated down-regulation of col1a1 gene was studied. TNF-K
increased extracellular-regulated kinase and Jun-N-terminal ki-
nase phosphorylation, but these e¡ects were not related to its
inhibitory e¡ect on K1(I) procollagen (col1a1) mRNA levels.
Phosphorylation of p38 MAPK was decreased in response to
TNF-K, and the speci¢c p38 MAPK inhibitor SB203580 mim-
icked the e¡ect of TNF-K on col1a1 mRNA levels. Transform-
ing growth factor L (TGF-L) increased p38 MAPK phosphory-
lation and SB203580 prevented the induction of col1a1 mRNA
levels by TGF-L. These results suggest that p38 MAPK plays
an important role in regulating the expression of col1a1 in he-
patic stellate cells in response to cytokines. 2 2002 Published
by Elsevier Science B.V. on behalf of the Federation of Euro-
pean Biochemical Societies.
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1. Introduction
Tumor necrosis factor K (TNF-K) is one of the main cyto-
kines involved in regulating proliferation and extracellular
matrix production by hepatic stellate cells (HSC), the cell
type responsible for collagen accumulation in the liver [1^3].
TNF-K down-regulates the expression of K1(I) and K2(I) pro-
collagen mRNAs in cultured HSC due to transcriptional in-
hibition of both genes [4,5]. The molecular mechanisms by
which TNF-K decreases the expression of collagen in HSC
have not been fully elucidated. It has been suggested that a
G protein could be involved in the inhibition of K1(I) procol-
lagen (col1a1) expression, and that sphingomyelin and ceram-
ide are two of the intracellular mediators of TNF-K [6].
Sphingomyelin breakdown by sphingomyelinases and the
consequent ceramide release have been demonstrated to me-
diate cell proliferation, di¡erentiation and apoptosis in di¡er-
ent cell types [7,8]. The diverse outcomes that result from
ceramide accumulation could be caused by the di¡erent sub-
cellular locations of sphingomyelin hydrolysis. There are two
main types of sphingomyelinases, the neutral sphingomyeli-
nase (N-SMase), and the acidic sphingomyelinase (A-SMase),
each isoform leading to ceramide formation within plasma-
lemmal and endosomal membranes, respectively [9]. Activa-
tion of SMases leads to phosphorylation and activation of
di¡erent members of the mitogen-activated protein kinase
(MAPK) family. The N-SMase activity has been related to
the activation of the extracellular-regulated kinase (ERK) cas-
cade, a signaling pathway involved in increased collagen pro-
duction by HSC and osteoclastic cells [10,11]. On the other
hand, A-SMase triggers the activation of the stress-activated
cascade, leading ¢nally to the activation of kinases like Jun-N-
terminal kinase (JNK) and p38 MAPK [12,13]. JNK activa-
tion has also been shown to be responsible for increased col-
lagen production induced by UV light in HSC [14]. However,
until now the relationship between MAPK activation by
TNF-K and the down-regulation of collagen production elic-
ited by this cytokine in HSC remained to be investigated.
In this report we studied the involvement of ERK, JNK
and p38 MAPK in the TNF-K-mediated down-regulation of
col1a1 mRNA levels in HSC. Our results indicate that p38
MAPK is a key mediator of the anti-¢brogenic e¡ect exerted
by TNF-K in HSC. The role played by p38 MAPK on the
regulation of col1a1 gene was further demonstrated using
transforming growth factor L (TGF-L) as an inductor of col-
lagen expression in HSC.
2. Materials and methods
2.1. Reagents
TNF-K and TGF-L were from Roche diagnostics (Barcelona,
Spain). Cell culture reagents were from Gibco BRL (Grand Island,
NY, USA). SB203580, SB202474 and PD98059 were purchased from
Calbiochem0 (Germany). L-JNKI1 was from ALEXIS0 Biochemicals
(Lausen, Switzerland). SR33557 was provided by Dr. Ja¡re'zou.
2.2. Cell culture and treatments
All the experiments were performed using the HSC line CFSC-2G
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[15]. Cells were cultured in minimum essential medium (MEM) sup-
plemented with 10% bovine fetal serum and non-essential amino acids
for 36 h, after which the medium was replaced for a serum-free MEM.
Treatments were carried out 12 h later.
Unless otherwise indicated, HSC were treated with either 10 ng/ml
TNF-K or 8 ng/ml TGF-L for 24 h, these concentrations and time of
treatment had been established in previous works [4,16]. In some
experiments cells were pretreated for 30 min with either 0.1 mM
SR33557, 10 WM SB203580 and SB202474, 10 WM PD98059 or 10
WM L-JNKI1. The speci¢city of these inhibitors at concentrations
used in the present study has been demonstrated in previous reports
[17^19].
2.3. Determination of oligonucleosomal (histone-associated)
DNA fragments
The presence of soluble histone^DNA complexes was measured by
the Cell Death Detection assay (Boehringer, Mannheim, Germany).
For this assay, HSC were seeded on 24-well plates at a density of
80 000 cells/well. Cell death enzyme-linked immunosorbent assays
were performed according to the manufacturer’s instructions. Speci¢c
enrichment of mono- and oligonucleosomes released into the cyto-
plasm (enrichment factor, EF) was calculated as the ratio between
the absorbance values of the samples obtained from treated and con-
trol cells.
2.4. RNA extraction and RT-PCR
Total RNA was extracted by the method of Chomczynski and
Sacchi [20]. Reverse transcription polymerase chain reaction (RT-
PCR) was performed using Platinum PCR Supermix kit (Invitrogen,
Carlsbad, CA, USA), following the manufacturer’s instructions. Total
RNA (0.75 Wg) was reverse-transcribed in a reaction volume of 20 Wl
by using 1 U/Wl murine leukemia virus reverse transcriptase at 42‡C.
PCR was performed by using the following primers: sense 5P-CT-
CTGGGATGATGGCTTGAG-3P and antisense 5P-TTCTTGAT-
CCTCGTCCCCAT-3P for nestin, and sense 5P-TGTGTGAAGAG-
GAAGACAGCAC-3P and antisense 5P-GCACAATACCAGTTGT-
ACGTCC-3P for K-SMA. After 5 min at 94‡C, both reactions were
carried out for 35 cycles with cycle times of 30 s at 94‡C, 30 s at 58‡C,
and 30 s at 72‡C, and one cycle of 7 min at 72‡C. The ampli¢ed
products were electrophoresed in 2% agarose gels, stained with ethid-
ium bromide, and photographed. The size of the products obtained
was 308 bp for nestin and 412 bp for K-SMA.
2.5. Northern blot analysis
Northern blot assays were performed using 10 Wg of total RNA per
lane and hybridization with 32P-labeled cDNA probes for col1a1 and
18S. Autoradiographic signals were quantitated by scanning densi-
tometry.
2.6. Western blot analysis of ERK phosphorylation
HSC were treated as described above and extracted in RIPA bu¡er.
Protein concentration of the resultant samples was determined by
Bradford assay. For immunoblotting analysis, equal amounts of pro-
tein were electrophoresed on sodium dodecyl sulfate^polyacrylamide
gels (SDS^PAGE) and transferred on membranes. Membranes were
incubated with a speci¢c antibody to ERK (Promega), or actin (Santa
Cruz Biotechnology, Santa Cruz, CA, USA). After incubation with
the secondary antibody conjugated to horseradish peroxidase (Prom-
ega), immunoreactive proteins were detected by enhanced chemilumi-
nescent system (ECL; Amersham International, Little Chalfont, UK).
2.7. Western blot analysis of JNK and p38 MAPK phosphorylation
Protein samples were obtained as described above, and samples
containing 300 Wg of total protein were incubated with 1 Wg anti-
phosphotyrosine monoclonal antibody (p-Tyr(PY20); Santa Cruz
Biotechnology) for 1 h at 4‡C. Immunocomplexes were recovered
by adsorption to agarose^protein A (Sigma, St. Louis, MO, USA).
After overnight incubation at 4‡C, immune complexes were harvested
with protein A^agarose, collected by centrifugation and washed four
times with RIPA bu¡er. Bound proteins were released from the par-
ticles by boiling for 5 min in SDS^PAGE sample bu¡er. Proteins were
electrophoresed and transferred on membranes and immunoblotted
with either anti-JNK or anti-p38 MAPK antibodies (New England
Biolabs). Immunoblots were carried out using the ECL method, and
signals were quantitated by scanning densitometry.
2.8. Statistical analysis
Data were analyzed using the Kruskal^Wallis test to determine
di¡erences between all independent groups. When signi¢cant di¡er-
ences were obtained (P6 0.05), di¡erences between two groups were
tested using the Mann^Whitney U-test.
3. Results
3.1. TNF-K is not pro-apoptotic for the cell line CFSC-2G
Apoptotic cell death is one of the most common and well
characterized e¡ects of TNF-K. However, the ability of TNF-
K to induce apoptosis depends on the cell type and in some
cases apoptosis only takes place when protein expression has
been inhibited at the transcriptional or translational levels
[21]. Prior to the study of the anti¢brogenic e¡ect of
TNF-K, we determined whether TNF-K treatment had an
apoptotic e¡ect on the cell line 2G-CFSC. The cytosolic ac-
cumulation of oligonucleosomal fragments, that re£ects the
extent of DNA fragmentation characteristic of apoptosis,
was analyzed as a parameter of apoptotic cell death.
Cells were treated with TNF-K (10 ng/ml) for 24 h in the
presence or absence of the protein synthesis inhibitor cyclo-
Fig. 1. A: Determination of oligonucleosomal fragments in cytoplas-
mic extracts from HSC treated with TNF-K, CHX or both. Oligo-
nucleosomal fragments content was expressed as enrichment factor
(EF), as described in Section 2. Each bar represents the meanVS.D.
of quadruplicate determinations. B: RT-PCR detection of nestin
and K-SMA. Products were resolved on 2% agarose gels and visual-
ized by UV following ethidium bromide staining.
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heximide (CHX; 100 Wg/ml). As shown in Fig. 1A, TNF-K
had no e¡ect on the accumulation of oligonucleosomal frag-
ments, unless protein synthesis had been blocked by CHX.
The resistance of HSC to apoptosis induced by TNF-K has
been previously reported and seems to be a consequence of
the activation process that takes place as a result of liver
damage or when cells are cultured [22]. Activated HSC are
characterized by up-regulation of type I collagen and expres-
sion of K-smooth muscle actin (K-SMA), nestin and others.
The cell line CFSC-2G presents low basal levels of expression
of type I collagen genes that can be up-regulated by cytokines
and growth factors [15]. However, by RT-PCR we found the
presence of messenger RNA for nestin and K-SMA (Fig. 1B).
Therefore, this cell line can be considered as a ‘transitional’
HSC, in which the activation process is already initiated.
3.2. ERK is phosphorylated in response to TNF-K
We ¢rst studied the role played by the ERK cascade in the
inhibitory action of TNF-K on col1a1 mRNA levels. TNF-K
treatment increased ERK1 and 2 phosphorylation 15 min
after adding the cytokine (Fig. 2A).
To determine if this e¡ect could be responsible for the
down-regulation of col1a1 elicited by TNF-K, we added the
MEK inhibitor PD98059 prior to treatment with TNF-K, and
analyzed by Northern blot its e¡ect on col1a1 mRNA levels.
Fig. 2. A: Analysis of ERK phosphorylation in TNF-K-treated
HSC. HSC were treated with 10 ng/ml TNF-K for the indicated
times and extracts were analyzed by Western blot as described in
Section 2. B: Northern blot analysis of col1a1 mRNA levels of
HSC treated with TNF-K and pretreated for 30 min with 10 WM
PD98059. Each bar represents the meanVS.D. of at least quadrupli-
cate experiments (*P6 0.05; a, vs. control; b, vs. TNF-K-treated
HSC). Values were corrected for loading di¡erences after hybridiza-
tion with a cDNA probe for 18S ribosomal RNA. A representative
Northern blot with the autoradiographic signals for col1a1 and 18S
ribosomal RNA is shown in the upper panel.
Fig. 3. Analysis of JNK and p38 MAPK phosphorylation in TNF-
K-treated HSC. HSC were treated with 10 ng/ml TNF-K for the in-
dicated times and immunoprecipitated extracts were analyzed by
Western blot as described in Section 2.
Fig. 4. E¡ect of the A-SMase inhibitor SR33557. A: Western blot
analysis of the e¡ect of SR33557 pretreatment on JNK and p38
MAPK phosphorylation levels in TNF-K-treated HSC. HSC were
treated with TNF-K as above and, when indicated, a 30 min pre-
treatment with 0.1 mM SR33557 was carried out. Results are repre-
sentative of at least three independent experiments. B: Northern
blot analysis of col1a1 mRNA levels of HSC treated with TNF-K
and SR33557. Each bar represents the meanVS.D. of at least qua-
druplicate experiments (*P6 0.05, ***P6 0.001; a, vs. control; b,
vs. TNF-K-treated HSC). Values were corrected for loading di¡eren-
ces after hybridization with a cDNA probe for 18S ribosomal
RNA. A representative Northern blot with the autoradiographic sig-
nals for col1a1 and 18S ribosomal RNA is shown in the upper pan-
el.
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As shown in Fig. 2B, PD98059 did not prevent the inhibitory
action of TNF-K.
3.3. TNF-K decreases p38 MAPK phosphorylation and
increases JNK phosphorylation in an
A-SMase-dependent fashion
The involvement of enzymes related to the stress-activated
cascade, JNK and p38 MAPK, in the e¡ect of TNF-K on
HSC was then evaluated. Western blot analysis of time-course
treatments with TNF-K revealed a di¡erent e¡ect for each
enzyme. JNK presented an increased phosphorylation in re-
sponse to TNF-K, reaching maximum values 5^15 min after
treatment, whereas p38 MAPK phosphorylation levels were
decreased by TNF-K, being ¢ve-fold lower compared to con-
trol levels 15 min after treatment (Fig. 3).
To establish if A-SMase mediated either e¡ect, HSC were
pretreated with SR33557, a potent A-SMase inhibitor [23].
SR33557 prevented the increased phosphorylation of JNK
as well as the decreased phosphorylation of p38 MAPK in-
duced by TNF-K (Fig. 4A), demonstrating both e¡ects to be
A-SMase-dependent. Northern blot analysis of the e¡ect of
SR33557 on col1a1 mRNA levels showed that blockage of
A-SMase signi¢cantly prevented the inhibitory e¡ect of
TNF-K (Fig. 4B).
3.4. Inhibition of p38 MAPK down-regulates col1a1 mRNA
levels
The e¡ect of speci¢c inhibitors for JNK and p38 MAPK
was evaluated. HSC were pretreated with SB203580, a pyri-
dinyl imidazole compound that has been described as an in-
hibitor of p38 MAPK [24], before adding TNF-K to the cell
cultures, and col1a1 mRNA levels were analyzed by Northern
blot. As shown in Fig. 5, SB203580 by itself mimicked the
anti-¢brogenic e¡ect of TNF-K, decreasing basal col1a1
mRNA levels. An additive inhibitory e¡ect on col1a1
mRNA levels was observed in HSC treated with both
SB203580 and TNF-K, reaching values of 80% inhibition, as
compared to untreated controls. Pretreatment with JNK in-
hibitor L-JNKI1 had no e¡ect on col1a1 mRNA levels, either
in control or TNF-K-treated HSC (Fig. 5).
Fig. 5. E¡ect of p38 MAPK and JNK inhibitors on the down-regu-
lation of col1a1 mRNA levels induced by TNF-K. HSC were treated
with 10 ng/ml TNF-K for 24 h. When indicated, a 30 min pretreat-
ment with 10 WM SB203580 or with 10 WM L-JNK-I1 was carried
out. Northern blot analysis was performed with 10 Wg of total
RNA. Each bar represents the meanVS.D. of at least quadruplicate
experiments (*P6 0.05; a, vs. control; b, vs. TNF-K-treated HSC).
Values were corrected for loading di¡erences after hybridization
with a cDNA probe for 18S ribosomal RNA. A representative
Northern blot with the autoradiographic signals for col1a1 and 18S
ribosomal RNA is shown in the upper panel.
Fig. 6. Time-course study of ERK, JNK and p38 MAPK phosphor-
ylation in TGF-L-treated HSC. HSC were treated with 8 ng/ml
TGF-L for the indicated times and extracts were analyzed by West-
ern blot. Results are representative of at least three independent ex-
periments.
Fig. 7. E¡ect of p38 MAPK and MEK inhibitors on the up-regula-
tion of col1a1 mRNA levels induced by TGF-L. HSC were treated
with 8 ng/ml TGF-L for 24 h. When indicated, a 30 min pretreat-
ment with 10 WM SB203580 or 10 WM PD98059 was carried out.
Northern blot analysis was performed with 10 Wg of total RNA.
Each bar represents the meanVS.D. of at least quadruplicate ex-
periments (*P6 0.05; a, vs. control; b, vs. TGF-L-treated HSC).
Values were corrected for loading di¡erences after hybridization
with a cDNA probe for 18S ribosomal RNA. A representative
Northern blot with the autoradiographic signals for col1a1 and 18S
ribosomal RNA is shown in the upper panel.
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3.5. p38 MAPK mediates the TGF-L-induced up-regulation of
col1a1 mRNA levels
The involvement of p38 MAPK in the regulation of colla-
gen expression by factors di¡erent from TNF-K was studied
using TGF-L as a pro-¢brogenic agent for HSC. Western blot
analysis of HSC treated with TGF-L showed an increased
phosphorylation in both ERK isoforms and in p38 MAPK,
while JNK phosphorylation levels remained unchanged (Fig.
6).
The e¡ect of MEK and p38 MAPK inhibitors on col1a1
mRNA was analyzed in TGF-L-treated HSC. As previously
reported [16], TGF-L up-regulated col1a1 mRNA levels.
Pretreatment with SB203580, but not PD98059, prevented
the increase of col1a1 mRNA levels induced by TGF-L in
HSC (Fig. 7). Similar experiments were carried out using
the inactive analog SB202474 as a negative control, ¢nding
that it had no e¡ect on the action of either TGF-L or TNF-K
on col1a1 mRNA levels (data not shown).
4. Discussion
TNF-K is one of the few cytokines known to produce a
decrease in collagen synthesis by activated HSC, and this
fact, together with the need for e¡ective anti-¢brogenic thera-
pies, makes the study of the molecular mechanisms responsi-
ble for this e¡ect particularly interesting.
The role played by members of the MAPK family on col-
lagen production by HSC has been studied in response to
several factors, with di¡erent results obtained depending on
the agent. ERK cascade has been shown to be related to
increased collagen production by HSC in response to IGF-I
[25], or as a consequence of the activation process character-
istic of this cell type [10]. JNK has been reported to become
phosphorylated and activated in HSC in response to UV ra-
diation, leading also to an increased collagen production [14].
Our results indicate that the ERK cascade is activated in HSC
by TNF-K and TGF-L, but that this activation is not related
to the anti- and pro-¢brogenic e¡ects exerted by each cytokine
respectively. JNK is also activated by TNF-K in HSC, but this
e¡ect does not seem to be responsible for the inhibition of
col1a1 mRNA levels, since JNK inhibitor L-JNKI1 did not
prevent it.
Several evidences suggest an important role for p38 MAPK
in the regulation of collagen production by HSC. Phosphor-
ylation levels of p38 MAPK are higher in activated HSC [26],
a phenotype characterized by a dramatic increase in type I
collagen synthesis, and inhibition of p38 MAPK both in qui-
escent and activated HSC has recently been reported to pro-
duce a decrease in col1a1 levels [18]. We found that treatment
of HSC with TNF-K led to a decreased phosphorylation of
p38 MAPK. The correlation between the inhibitory action of
TNF-K on col1a1 mRNA and its e¡ect on p38 MAPK phos-
phorylation levels, and the fact that both e¡ects were A-
SMase-dependent, suggested a relationship between the two
events. Moreover, inhibition of p38 MAPK by SB203580
mimicked the e¡ect of TNF-K on col1a1 mRNA levels and,
added together with TNF-K, produced a higher extent of in-
hibition. Taken together, these results suggest that activation
of A-SMase by TNF-K results in phosphorylation and activa-
tion of JNK, and inactivation of p38 MAPK by dephosphor-
ylation, the latter e¡ect leading to col1a1 inhibition.
To establish whether p38 MAPK is also involved in the up-
regulation of collagen production by HSC, we carried out
experiments using TGF-L as an inductor of collagen expres-
sion. TGF-L up-regulates collagen expression in several cell
types, including cultured HSC [16]. In addition, in other cell
types the pro-¢brogenic e¡ect of TGF-L has been shown to be
mediated by p38 MAPK activation [27,28]. Treatment of HSC
with TGF-L resulted in an increased phosphorylation of p38
MAPK that correlated with increased col1a1 mRNA levels in
response to this cytokine, and the p38 MAPK inhibitor
SB203580 prevented the pro-¢brogenic e¡ect of TGF-L,
strongly suggesting that p38 MAPK participates also in the
up-regulation of col1a1 by TGF-L.
Recently published data demonstrate that TNF-K and
TGF-L-responsive elements co-localize in the col1a1 gene pro-
moter [29]. Our ¢ndings point to another level of convergence
for TNF-K and TGF-L, namely, intracellular signal transduc-
tion through p38 MAPK phosphorylation. Further studies
would be needed to establish whether the transductional and
transcriptional e¡ects of these cytokines are related.
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